decemb
novel
coronaviru
name
sever
acut
respiratori
syndrom
coronaviru
emerg
china
caus
pneumonia
outbreak
first
wuhan
region
china
spread
worldwid
probabl
high
transmiss
effici
owe
lack
effici
specif
treatment
need
contain
epidem
drug
repurpos
appear
best
tool
find
therapeut
solut
chloroquin
remdesivir
lopinavir
ribavirin
ritonavir
shown
efficaci
inhibit
coronaviru
vitro
teicoplanin
antibiot
use
treat
staphylococc
infect
previous
show
efficaci
inhibit
first
stage
middl
east
respiratori
syndrom
coronaviru
merscov
viral
life
cycl
human
cell
activ
conserv
thu
place
teicoplanin
potenti
treatment
patient
viru
elsevi
bv
intern
societi
chemotherapi
right
reserv
decemb
novel
coronaviru
emerg
china
caus
pneumonia
outbreak
first
wuhan
region
china
spread
worldwid
probabl
high
transmiss
effici
coronaviru
name
sever
acut
respiratori
syndrom
coronaviru
formerli
respons
respiratori
infect
includ
pneumonia
estim
mortal
rate
approxim
increas
age
presenc
underli
diseas
first
day
march
estim
case
confirm
worldwid
world
health
organ
number
like
underestim
due
exist
asymptomat
carrier
epidem
alreadi
left
dead
coronaviru
diseas
major
occur
china
becom
pandem
absenc
known
valid
effici
therapi
effort
laboratori
medic
team
focus
repurpos
us
food
drug
administr
fda
approv
drug
treat
sever
case
drug
repurpos
effect
way
quickli
identifi
therapeut
drug
known
safeti
profil
treat
emerg
diseas
chloroquinehydroxychloroquin
frontlin
drug
use
treatment
prophylaxi
malaria
well
autoimmun
diseas
shown
inhibit
replic
sever
dna
rna
virus
includ
human
coronavirus
recent
chloroquin
found
inhibit
vitro
hydroxyl
form
propos
possibl
therapi
treat
patient
infect
context
drug
also
show
signific
efficaci
vitro
includ
remdesivir
lopinavir
ribavirin
ritonavir
http
drugvirusinfo
teicoplanin
glycopeptid
antibiot
routin
use
treat
bacteri
infect
found
activ
vitro
sarscov
join
list
molecul
could
use
therapeut
arsen
antibiot
current
use
treatment
gramposit
bacteri
infect
especi
staphylococc
infect
alreadi
shown
efficaci
variou
virus
ebola
viru
influenza
viru
flaviviru
hepat
c
viru
human
immunodefici
viru
hiv
well
coronavirus
middl
east
respiratori
syndrom
coronaviru
merscov
sarscov
patent
file
treatment
infect
caus
merscov
accord
zhou
et
al
coronavirus
teicoplanin
act
earli
stage
viral
life
cycl
inhibit
lowph
cleavag
viral
spike
protein
cathepsin
l
late
endosom
therebi
prevent
releas
genom
viral
rna
continu
viru
replic
cycl
recent
studi
author
show
activ
conserv
target
sequenc
serv
cleavag
site
cathepsin
l
conserv
among
sarscov
spike
protein
concentr
teicoplanin
requir
inhibit
virus
ic
vitro
much
lower
concentr
reach
human
blood
daili
dose
mg
preliminari
result
need
confirm
randomis
clinic
trial
base
experi
teicoplanin
use
treatment
infecti
diseas
encourag
investig
antivir
effect
molecul
suggest
teicoplanin
anoth
potenti
altern
treatment
fund
work
support
french
govern
investiss
davenir
invest
futur
programm
manag
agenc
national
de
la
recherch
anr
refer
infect
work
support
provenc
alp
dazur
european
fund
feder
primi
